AGR2 and chronic myelogenous leukemia, BCR-ABL1 positive: Similarly, the silencing of AGR2 using the overexpression of miR-217 in the CML cell line K562, which is dasatinib resistant, restored the cells’ sensitivity to dasatinib treatment [82].